The International Neuromodulation Society

The Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of Neuromodulation

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, explanatory content, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.

The INS Peer-Reviewed Journal – 8 Issues a Year

The INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online.

journal cover

+Submit a Manuscript.+

What is Neuromodulation?

Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application.

Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:

If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.

Members may log in and visit the members-only section’s Global Discussion Forum

Breaking News Share

News Article Recaps Research Regarding Occipital Nerve Stimulation

July 16, 2019 - An article in Neuromodulation: Technology at the Neural Interface reports on burst occipital nerve stimulation in patients with chronic migraine and chronic cluster headache. (Neurology Advisor)

Neurostimulation Company Acquires Sensing-and-Stimulation Technology

July 16, 2019 - Nia Therapeutics, Inc. has acquired integrated circuit technology for brain sensing and stimulation developed by Cortera Neurotechnologies, Inc. Nia plans to use the technology as the core of its system for treating memory impairment. (Medium)

Review Covers Evidence and Future Design of Sham- and Placebo-Controlled Trials of Spinal Cord Stimulation

July 15, 2019 - An international team of authors reviewed randomized controlled trials of spinal cord stimulation (SCS) involving sham or placebo. They developed a checklist for the future design and reporting of SCS randomized controlled trials. (Neuromodulation: Technology at the Neural Interface)

Review: Neurorestorative Implants After Spinal Cord Surgery

July 11, 2019 - An article discusses the emerging role of implanted medical devices for improving functional recovery after spinal cord injury, such as research into brain-computer interfaces to augment physical rehabilitation. The article also notes that neuromodulation therapies that target the brain or spinal cord have helped improve motor and autonomic functions. (Bioelectronic Medicine)

Review Covers Intrathecal Drug Delivery Devices

July 15, 2019 - A review covers recent advances and future developments in intrathecal drug delivery for pain management. (Expert Opinion on Drug Delivery)

Headache Society Presentations Include Neurostimulation for Cluster Headache or Episodic Migraine

July 11, 2019 - An article about advancements in therapies being presented at the American Headache Society annual meeting mentions FDA approval of noninvasive vagus nerve stimulation in the past 12 months as an adjunct in prevention of cluster headache. The article also mentioned studies about a sphenopalatine ganglion microstimulator implant for terminating acute cluster attacks in patients with refractory chronic cluster headache. Data were presented at the meeting about noninvasive vagus nerve stimulation mechanisms and effectiveness in relief of episodic migraine. (Neurology Times)

CE Mark Granted for Migraine Relief Device

July 10, 2019 - Neurolief announced it received CE mark to market its noninvasive neurostimulation device for the relief of acute migraine as an over-the-counter device within the European Union. (Neuro News)

Article Surveys Current and Potential Treatments Involving Vagus Nerve Stimulation

July 10, 2019 - An article discusses advances in vagus nerve stimulation for migraine prevention and research into new potential applications, such as fighting lung infection in pre-term babies. (Leaps Magazine)

To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.

Continue Reading News Briefs
Last Updated on Monday, December 12, 2016 10:01 AM